ATANIS Biotech AG

We are #hiring for three positions! Tell your network, or come join us in Bern to help revolutionize Allergy Diagnosis. Executive Assistant / Office Manager https://lnkd.in/e5HJnF2p Research Assistant in Design & Development https://lnkd.in/e3qHGetn Quality Assurance Release Specialist https://lnkd.in/e7HYtPgv

We are delighted to announce completion of an oversubscribed Capital Increase. This is an important stepping stone on our way to revolutionize allergy diagnosis.

New allergy test shows diagnostic accuracy of 95% 🎯   Researchers at the University of Bern and Bern University Hospital have developed a test to simplify the diagnosis of allergies. Its effectiveness has now been confirmed in clinical samples from children and adolescents suffering from a peanut allergy. 👍 The new test showed significantly higher accuracy than standard measurements or tests: “An exceptionally high diagnostic accuracy of 95% could be calculated from our data,” says Prof. Dr. Alexander Eggel from the Department for BioMedical Research (DBMR) at the University of Bern and the Department of Rheumatology and Immunology, Bern University Hospital. He co-led the research team together with Prof. Dr. Thomas Kaufmann from the Institute of Pharmacology at the University of Bern.   👍 The results could fundamentally improve the clinical diagnosis of allergies in the future: “What has been shown in this study on the diagnosis of peanut allergies can also be applied to other allergies in a simple way. The technology is a perfect example of how basic research from the University of Bern can be brought to the clinical practice, and might ultimately simplify life for patients and physicians,” says Alexander Eggel.   ▶ To the media release: https://lnkd.in/dnW8XfVY ▶ To the original publication in the European Journal of Allergy and Clinical Immunology (open access): https://lnkd.in/dcnXCnYv Universität Bern Insel Gruppe

In this recent Allergy EAACI publication our FAST-PASE technology has been thoroughly validated in the academic setting using clinical samples of peanut allergic patients and healthy controls! With sensitivity and specificity of 93% and 96%, respectively, FAST-PASE showed a remarkable diagnostic accuracy, which was higher than commonly used techniques including specific IgE measurement and skin prick test. This is exciting news for ATANIS Biotech AG, as we will bring this test to the market. Congratulations to all authors, especially to the #MonasWorkingGroup for collecting the samples. https://lnkd.in/eqvVstmd @Alper Celik Nadine Roos, Melanie Steinmann @Jennifer A. Hoang @Xiaojun Yin Christina Maria Ditlof, MSc @Lucy Duan @Julia E. M. Upton Thomas Eiwegger and our teammembers Noemi Bachmeier-Zbären, Rosa Robin van Brummelen, Thomas Kaufmann & Alexander Eggel

Developing a novel cell-based diagnostic test that performs reliably is no easy task. It requires rigorous validation in a real-world patient cohort, with appropriate controls and blinded assessments. Demonstrating its clinical utility against current state-of-the-art diagnostics with favorable outcomes is the true measure of success. I'm excited to share that we've achieved all of the above with our Hoxb8 mast cell activation test #Hoxb8MAT in our recent study on peanut allergy diagnosis, now published in Allergy EAACI. A big thank you to our collaborators from The Hospital for Sick Children in Toronto, Canada who made this possible! Next steps - to make this exciting test available to clinicians & patients in an #IVDR/ FDA certified manner! #GoalsFor2025 Thomas Eiwegger, Thomas Kaufmann, Julia Upton, Noemi Bachmeier-Zbären, Rosa Robin van Brummelen, Alper Celik, Melanie Steinmann, Nadine Roos, University of Bern, Department for BioMedical Research DBMR, Lung Precision Medicine (LPM) DBMR Bern, The Hospital for Sick Children, ATANIS Biotech AG, Jean-Pierre Kinet, FARE, Innovation Office University of Bern, European Academy of Allergy and Clinical Immunology - EAACI, Rheumatologie_Immunologie Bern

🌟 20 Emerging BioTech Startups to Watch in 2025 🌟 Can you believe how fast 2024 is speeding by? Before we know it, we'll be stepping into 2025! As we get ready for the new year, I wanted to explore some of the most exciting biotech startups poised to make a big impact. From groundbreaking cancer therapies to sustainable superfoods, these 20 companies are set to redefine industries and drive innovation forward. Gene editing like CRISPR/Cas9 is making headlines, offering the potential to cure genetic diseases and boost agriculture. 🌾 Meanwhile, synthetic biology is creating new biological systems for everything from biofuels to advanced pharmaceuticals. Plus, AI is supercharging biotech research, helping scientists unlock new insights into diseases and drug development. Let's take a closer look at the 20 dynamic BioTech startups that are contributing to these transformative innovations and beyond in 2025: 🩺 Hera Biotech – Non-surgical endometriosis diagnosis 🌿 ATANIS Biotech AG – Functional allergy screening 🧬 Andson Biotech – Streamlining mass spectrometry 🦠 metaBIX Biotech – Pathogen risk detection 🧬 MxT Biotech – Microfluidic gene editing ♻️ Entomal Biotech – Mobile bio-conversion systems 🌱 Home Algae Biotechnology – Algae-derived ingredients 💪 Quantis – Human bioidentical proteins 🔒 Aclid – Gene synthesis security ☁️ LatchBio – Cloud-based bioinformatics 🏭 SUMATRIX BIOTECH – Biofabricated materials 💊 PharmAla Biotech Inc. (MDMA.CSE) – Clinical MDMA 🧬 Glyphic Biotechnologies – Next-gen protein sequencing 🔥 RAGE Biotech – Chronic inflammatory disease treatment 🦠 HHV Biotech – Biofilm-related therapeutics 🎯 Optieum Biotechnologies Inc. – Antibody-based cancer therapies 🧠 Gate2Brain – Therapeutic-peptide shuttles 💉 Lumatix Biotech – Antibody manufacturing 🌿 HydRegen – Sustainable chemical synthesis 🍽️ NEWFISH – Microalgae-based superfoods 💡 Which of these biotech innovations will make the biggest impact? Share your thoughts! 👇 Source: startus-insights #biotech2025 #genetherapy #crispr #biotechstartups #futureofhealthcare #sustainableinnovation #aibiotech #syntheticbiology #personalizedmedicine #bioinformatics #greenchemistry #superfoods #pharmaceuticals #innovation2025 #healthtech #emergingtech #biomaterials #clinicaltrials #sustainablefood #algaebased

We're delighted to see our HoxB8 mast cell activation test (MAT) being used to assess the pre-clinical efficacy of the peanut-specific IgG drug candidate IGNX001. Congratulations Jessica Grossman MD, Derek Croote and team for the recent publication in JACI, and thanks to everyone at IgGenix, Inc for being such wonderful collaborators. Together, we will upend Allergy Care from diagnosis to treatment. https://lnkd.in/e3E-q59D

Have you ever wanted to deep dive into the inner workings of our MAT Test, and to understand why we think it will be revolutionary for food allergy patients? Have all your questions answered in this interview of our co-founders Jean-Pierre Kinet and Alexander Eggel by Allergic Living Magazine. #RevolutionizeAllergyDiagnosis, #FunctionalDiagnostics, #MastCellActivationTest, #UnderstandAllergies

Thanks to the Food Allergy Fund for inviting us to this fascinating panel discussion in New York City! Listen in on this expert panel led by Prof. Hugh Sampson, and better understand how Siolta Therapeutics aims to stop allergic disease by intervening early in high-risk infants; how IgGenix, Inc adresses allergic disease directly by blocking the allergic cascade; and how our own diagnostic test may prove much safer for the patient and much less cumbersome than the oral food challenge. #RevolutionizeAllergyDiagnostics, Jean-Pierre Kinet, Jessica Grossman MD, Nikole Kimes, iXLife Capital, AllerFund, Lisa Shapiro Strovink

We are hiring a motivated cell culture technician! Apply here: